CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Conversion Of Convertible Notes	Common stock	Common stock Conversion Of Convertible Notes	Additional paid in capital	Additional paid in capital Conversion Of Convertible Notes	Acc. Other Comprehensive Income	Treasury stock	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2023			157,287,522
Beginning balance at Dec. 31, 2023	$ (29,999)		$ 17		$ 303,428		$ 0	$ (57,350)	$ (276,094)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(142,231)								(142,231)
Foreign currency translation adjustments, net of tax	0
Equity-based compensation expense	10,906				10,906
Exercise of options (in shares)			87,324
Exercise of options	119				119
Issuance of shares for equity-based compensation awards, net (in shares)			4,311,703
Issuance of shares for equity-based compensation awards, net	(3,140)				(3,140)
Issuance of common shares as consideration for the acquisition of Pangiam (in shares)			61,838,072
Issuance of common shares as consideration for the acquisition of Pangiam	207,776		$ 6		207,770
Issuance of shares upon conversion or exercise (in shares)			22,775,144
Issuance of shares upon conversion or exercise	90,707		$ 2		90,705
Issuance of shares for exercised convertible notes (in shares)			94
Issuance of shares purchased under ESPP (in shares)			474,325
Issuance of shares purchased under ESPP	607				607
Ending balance (in shares) at Jun. 30, 2024			246,774,184
Ending balance at Jun. 30, 2024	134,745		$ 25		610,395		0	(57,350)	(418,325)
Beginning balance (in shares) at Mar. 31, 2024			246,061,379
Beginning balance at Mar. 31, 2024	143,173		$ 25		604,384		0	(57,350)	(403,886)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(14,439)								(14,439)
Foreign currency translation adjustments, net of tax	0
Equity-based compensation expense	5,749				5,749
Exercise of options (in shares)			22,780
Exercise of options	33				33
Issuance of shares for equity-based compensation awards, net (in shares)			215,700
Issuance of shares for equity-based compensation awards, net	(378)				(378)
Issuance of shares purchased under ESPP (in shares)			474,325
Issuance of shares purchased under ESPP	607				607
Ending balance (in shares) at Jun. 30, 2024			246,774,184
Ending balance at Jun. 30, 2024	$ 134,745		$ 25		610,395		0	(57,350)	(418,325)
Beginning balance (in shares) at Dec. 31, 2024	251,554,378		251,554,378
Beginning balance at Dec. 31, 2024	$ (3,714)		$ 26		625,130		121	(57,350)	(571,641)
Ending balance (in shares) at Mar. 31, 2025			289,052,369
Ending balance at Mar. 31, 2025	$ 197,795		$ 31		888,608		133	(57,350)	(633,627)
Beginning balance (in shares) at Dec. 31, 2024	251,554,378		251,554,378
Beginning balance at Dec. 31, 2024	$ (3,714)		$ 26		625,130		121	(57,350)	(571,641)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(290,605)								(290,605)
Foreign currency translation adjustments, net of tax	(270)						(270)
Equity-based compensation expense	$ 11,719				11,719
Exercise of options (in shares)	1,319,949		1,125,214
Exercise of options	$ 1,633				1,633
Issuance of shares for paid-in-kind interest on 2029 Notes (in shares)			1,084,119
Issuance of shares for paid-in-kind interest on 2029 Notes	4,095				4,095
Issuance of shares for equity-based compensation awards, net (in shares)			6,124,374
Issuance of shares for equity-based compensation awards, net	(1,679)		$ 2		(1,681)
Issuance of shares upon conversion or exercise (in shares)			14,800,000	16,658,335
Issuance of shares upon conversion or exercise	113,953	$ 135,599	$ 1	$ 2	113,952	$ 135,597
Issuance of shares from at-the-market offering (in shares)			77,253,313
Issuance of shares from at-the-market offering	294,750		$ 8		294,742
Issuance of shares purchased under ESPP (in shares)			571,875
Issuance of shares purchased under ESPP	$ 1,069				1,069
Ending balance (in shares) at Jun. 30, 2025	369,171,608		369,171,608
Ending balance at Jun. 30, 2025	$ 266,550		$ 39		1,186,256		(149)	(57,350)	(862,246)
Beginning balance (in shares) at Mar. 31, 2025			289,052,369
Beginning balance at Mar. 31, 2025	197,795		$ 31		888,608		133	(57,350)	(633,627)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(228,619)								(228,619)
Foreign currency translation adjustments, net of tax	(282)						(282)
Equity-based compensation expense	4,319				4,319
Exercise of options (in shares)			141,780
Exercise of options	240				240
Issuance of shares for paid-in-kind interest on 2029 Notes (in shares)			1,084,119
Issuance of shares for paid-in-kind interest on 2029 Notes	4,095				4,095
Issuance of shares for equity-based compensation awards, net (in shares)			3,004,152
Issuance of shares for equity-based compensation awards, net	(362)				(362)
Issuance of shares from at-the-market offering (in shares)			75,317,313
Issuance of shares from at-the-market offering	288,295		$ 8		288,287
Issuance of shares purchased under ESPP (in shares)			571,875
Issuance of shares purchased under ESPP	$ 1,069				1,069
Ending balance (in shares) at Jun. 30, 2025	369,171,608		369,171,608
Ending balance at Jun. 30, 2025	$ 266,550		$ 39		$ 1,186,256		$ (149)	$ (57,350)	$ (862,246)